Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis

Pain Due to Osteoporosis Clinical Trial

Official title: Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis

Status Completed

Clinical Trial Summary

The purpose of this study is to examine the efficacy and safety of OPC-249 by once daily inhalation at 0 (placebo), 30, 60 or 120 IU for 4 weeks in patients with pain due to osteoporosis.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Osteoporosis
• Pain Due to Osteoporosis

• NCT number: NCT00504426
• Study type: Interventional
• Source: Otsuka Pharmaceutical Co., Ltd.
• Status: Completed
• Phase: Phase 2
• Start date: July 2007
• Completion date: May 2009